MINAPHARM Pharmaceuticals (EGX:MIPH)

MINAPHARM Pharmaceuticals Balance Sheet

Financials in millions EGP. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,885	1,918	1,694	981.94	1,024
Short-Term Investments	5	-	-	-	-
Cash & Short-Term Investments	2,890	1,918	1,694	981.94	1,024
Cash Growth	50.70%	13.25%	72.47%	-4.06%	33.96%
Accounts Receivable	647.52	492.9	478.14	388.76	331.91
Other Receivables	76.37	46.13	12.22	5.52	5.67
Receivables	1,005	742.76	575.06	399.59	358.93
Inventory	1,233	1,055	838.28	668.51	587.16
Prepaid Expenses	30.33	10.76	12.41	6.54	5.89
Other Current Assets	558.59	315.92	524.8	345.77	205.54
Total Current Assets	5,717	4,042	3,644	2,402	2,181
Property, Plant & Equipment	5,687	4,251	2,685	1,340	1,004
Long-Term Investments	-	5	5	5	5
Goodwill	339.97	334.51	280.08	220.53	230.21
Other Intangible Assets	254.84	67.1	56.9	48.2	62.16
Long-Term Deferred Tax Assets	-	-	-	-	0.81
Other Long-Term Assets	4.92	3.22	134.67	89.77	-
Total Assets	12,003	8,704	6,806	4,106	3,483
Accounts Payable	1,189	735.34	677.29	416.64	508.39
Accrued Expenses	47.34	46.81	39.23	31.53	26.18
Short-Term Debt	2,191	2,043	1,042	542.29	747.41
Current Portion of Long-Term Debt	398.09	218.67	225.33	32.93	23.24
Current Portion of Leases	55.35	27.77	15.1	68.13	-
Current Income Taxes Payable	195.94	134.82	233.36	183.69	151.54
Current Unearned Revenue	14.62	9.81	7.45	5.04	4.44
Other Current Liabilities	495.28	314.7	261.3	208.89	168.76
Total Current Liabilities	4,587	3,531	2,501	1,489	1,630
Long-Term Debt	2,250	1,335	1,036	603.87	187.84
Long-Term Leases	562.68	153.62	114.83	1.17	-
Long-Term Deferred Tax Liabilities	27.54	44.99	56.01	22.69	18.53
Other Long-Term Liabilities	167.5	121.15	57.52	45.73	53.43
Total Liabilities	7,594	5,186	3,765	2,163	1,890
Common Stock	117.81	122.93	122.93	122.93	122.93
Retained Earnings	2,053	2,147	2,023	1,466	1,047
Treasury Stock	-	-69.63	-69.63	-	-
Comprehensive Income & Other	2,135	1,222	882.83	293.27	367.67
Total Common Equity	4,306	3,423	2,959	1,882	1,537
Minority Interest	102.74	94.61	81.82	61.29	56.04
Shareholders' Equity	4,409	3,517	3,041	1,943	1,593
Total Liabilities & Equity	12,003	8,704	6,806	4,106	3,483
Total Debt	5,457	3,779	2,433	1,248	958.49
Net Cash (Debt)	-2,566	-1,861	-739.64	-266.46	65.01
Net Cash Per Share	-231.95	-168.18	-64.46	-21.67	5.29
Filing Date Shares Outstanding	11.78	11.06	11.06	12.29	12.29
Total Common Shares Outstanding	11.78	11.06	11.06	12.29	12.29
Working Capital	1,130	511.26	1,143	913.2	551.05
Book Value Per Share	365.53	309.35	267.42	153.07	125.04
Tangible Book Value	3,711	3,021	2,622	1,613	1,245
Tangible Book Value Per Share	315.04	273.05	236.96	131.21	101.26
Land	55.2	39.7	33.23	26.15	27.3
Buildings	1,579	508.65	411.79	296.6	307.09
Machinery	2,505	1,777	1,365	977.94	961.26
Construction In Progress	2,988	2,936	1,666	666.97	357.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.